WUHN - Wuhan General Group (China), Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Wuhan General Group (China), Inc.

Ganduxer 32, 1-1
Barcelona 08021
34 600 11 57 89

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees700

Key Executives

NameTitlePayExercisedYear Born
Ms. Carol PanPrincipal Financial Officer, Principal Accounting Officer and Treasurer60kN/A1984
Mr. Jeffrey RobinsonChairman & CEON/AN/AN/A
Dr. Hyder Ali KhojaChief Scientific OfficerN/AN/AN/A
Dr. Anna Leralta MoreraChief Medical OfficerN/AN/AN/A
Mr. Luka MarjanovicHead of Product Devel. for the MJ MedTech in South AfricaN/AN/AN/A
Amounts are as of December 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Barcelona, Spain.

Corporate Governance

Wuhan General Group (China), Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.